S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
NASDAQ:GERN

Geron - GERN Stock Forecast, Price & News

$3.34
-0.03 (-0.89%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.32
$3.41
50-Day Range
$2.04
$3.40
52-Week Range
$0.99
$3.84
Volume
3.64 million shs
Average Volume
17.15 million shs
Market Capitalization
$1.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Geron MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
64.7% Upside
$5.50 Price Target
Short Interest
Healthy
5.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.15
Upright™ Environmental Score
News Sentiment
0.47mentions of Geron in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.38) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

445th out of 1,054 stocks

Pharmaceutical Preparations Industry

219th out of 517 stocks


GERN stock logo

About Geron (NASDAQ:GERN) Stock

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

GERN Stock News Headlines

Geron (NASDAQ:GERN) Upgraded by StockNews.com to "Sell"
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Why Is Geron (GERN) Stock Soaring 50% Today?
These 2 Nasdaq Biotechs Are Making Big Moves Wednesday
Why Is Axsome (AXSM) Up 18.6% Since Last Earnings Report?
Geron: Expect Topline MDS Data In Early January
Geron to Participate in Stifel 2022 Healthcare Conference
Geron (GERN) Q3 2022 Earnings Call Transcript
See More Headlines
Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

GERN Company Calendar

Last Earnings
11/03/2022
Today
1/29/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GERN
CUSIP
37416310
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+64.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-116,110,000.00
Net Margins
-8,563.80%
Pretax Margin
-8,563.80%

Debt

Sales & Book Value

Annual Sales
$1.39 million
Book Value
$0.39 per share

Miscellaneous

Free Float
358,361,000
Market Cap
$1.27 billion
Optionable
Optionable
Beta
0.76

Key Executives

  • Dr. John A. Scarlett M.D. (Age 72)
    Chairman, Pres & CEO
    Comp: $1.26M
  • Ms. Olivia Kyusuk Bloom (Age 54)
    Exec. VP of Fin., CFO & Treasurer
    Comp: $743.27k
  • Dr. Andrew J. Grethlein (Age 59)
    Exec. VP & COO
    Comp: $767.28k
  • Ms. Melissa A. Kelly Behrs (Age 59)
    Exec. VP of Bus. Operations & Chief Alliance Officer
    Comp: $753.22k
  • Mr. Anil Kapur (Age 53)
    Exec. VP of Corp. Strategy & Chief Commercial Officer
    Comp: $654.89k
  • Ms. Aron Feingold
    VP of Investor Relations & Corp. Communications
  • Mr. Stephen N. Rosenfield J.D. (Age 73)
    Exec. VP, Chief Legal Officer & Corp. Sec.
  • Ms. Shannon Odam
    VP of HR
  • Mr. Edward E. Koval (Age 61)
    Exec. VP & Chief Bus. Officer
  • Dr. Faye Feller M.D. (Age 41)
    Exec. VP & Chief Medical Officer













GERN Stock - Frequently Asked Questions

Should I buy or sell Geron stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares.
View GERN analyst ratings
or view top-rated stocks.

What is Geron's stock price forecast for 2023?

4 brokers have issued 1-year target prices for Geron's shares. Their GERN share price forecasts range from $4.00 to $7.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 64.7% from the stock's current price.
View analysts price targets for GERN
or view top-rated stocks among Wall Street analysts.

How have GERN shares performed in 2023?

Geron's stock was trading at $2.42 on January 1st, 2023. Since then, GERN shares have increased by 38.0% and is now trading at $3.34.
View the best growth stocks for 2023 here
.

Are investors shorting Geron?

Geron saw a drop in short interest in January. As of January 15th, there was short interest totaling 22,710,000 shares, a drop of 22.2% from the December 31st total of 29,190,000 shares. Based on an average daily trading volume, of 8,130,000 shares, the days-to-cover ratio is presently 2.8 days.
View Geron's Short Interest
.

When is Geron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our GERN earnings forecast
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) issued its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.01. The biopharmaceutical company earned $0.30 million during the quarter, compared to the consensus estimate of $0.12 million. Geron had a negative trailing twelve-month return on equity of 110.76% and a negative net margin of 8,563.80%.

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Geron own?
What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by many different retail and institutional investors. Top institutional investors include Douglas Lane & Associates LLC (0.02%), Allspring Global Investments Holdings LLC (0.01%), Private Advisor Group LLC (0.01%) and Tennessee Valley Asset Management Partners (0.00%).
View institutional ownership trends
.

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $3.34.

How much money does Geron make?

Geron (NASDAQ:GERN) has a market capitalization of $1.27 billion and generates $1.39 million in revenue each year. The biopharmaceutical company earns $-116,110,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for the company is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at investor@geron.com, or via fax at 650-473-7750.

This page (NASDAQ:GERN) was last updated on 1/29/2023 by MarketBeat.com Staff